![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MAYNE CONTINUES DEVELOPMENT OF PLIVA G-CSF
MAYNE CONTINUES DEVELOPMENT OF PLIVA G-CSF
PLIVA, headquartered at Croatia, has finalized an agreement with Mayne Pharma of Australia, for the continued development of biosimilar granulocyte-colony stimulating factor (G-CSF) for the European, South East Asian, Middle Eastern and Asia Pacific markets.
BioSpectrum (http://www.biospectrumasia.com/content/280706AUS1235.asp)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct